Table 3 Clinical outcomes of studies utilising platelet-rich plasma
Study | Type of Osteotomy Performed | Intervention | Number of Patients in Intervention Group | Number of Patients in Control Group | Number of Patients undergoing second-look Arthroscopy | Pre-OP VAS Score | Post-OP VAS score | Pre-OP Kanamiya Grading | Post-Op Kanamiya Grading | Pre-OP Lysholm Score | Post-OP Lysholm Score | Pre-OP KOOS Score | Post-OP KOOS Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
D’Elia et al, Revista Brasileira de Ortopedia 2015 [19] | HTO | PRP with BMAC | 11 | 14 | N.A | Not Reported | Not Reported | Not Reported | Not Reported | Not Reported | Not Reported | Not Reported | |
Koh et al, Arthroscopy 2014 [21] | HTO | PRP with Adipose- derived MSC | 21 | 23 | 44/44 patients at mean 19.8 months post-op | PRP (control) (n = 23) v PRP-MSC (n = 21) 45.4 ± 7.1 v 44.3 ± 5.7 | Not Reported | PRP (control) (n = 23) v PRP-MSC (n = 21) Grade I: 11 (47.8%) v 1 (4.8%) Grade II: 11 (47.8%) v 9 (42.9%) Grade III: 1 (4.3%) v 8 (38.1%) Grade IV: 0 (0%) v 3 (14.3%) | PRP (control) (n = 23) v PRP-MSC (n = 21) 56.7 ± 12.2 v 55.7 ± 11.5 | PRP (control) (n = 23) v PRP-MSC (n = 21) At latest follow-up (mean 24.6 months (PRP) and 24.2 months (PRP-MSC)) 80.6 ± 13.5 v 84.7 ± 16.2 | Not Reported | PRP (control) (n = 23) v PRP-MSC (n = 21) At latest follow-up (mean 24.6 months (PRP) and 24.2 months (PRP-MSC)): Pain subscale: 74.0 ± 5.7 v 81.2 ± 6.9 Symptom subscale: 75.4 ± 8.5 v 82.8 ± 7.2 |